FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/10/2022
Back to search
Official data from USPTO
BIOARCTIC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
BIOARCTIC
ST13
US500000079309164Class
1, 5, 10, 42, 44, 45
Filing
79309164
Registration
6749255
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
10/10/2022
Trademark type
Word
Nice classes
1, 5, 10, 42, 44, 45
Filing date
12/14/2020
Registration date
06/07/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/07/2022
Last transaction
06/10/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
09
Owner location
SE
Examiner
BURKE, JUSTINE
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
BioArctic AB
Representatives
Jessica S. Sachs Harness, Dickey & Pierce, PLC
Technical classification
Nice Classes
Class 1Class 5Class 10Class 42Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical substanceschemical materialschemical preparationsnon-synthetic elements for use in the manufacture of pharmaceuticals; chemical substances and materials for industrialscientific and laboratory useother than for medical or veterinary purposes; biochemical preparations for scientific purposes for use in the manufacture of pharmaceuticals; chemical substances for use in the production of drugspharmaceuticals and antibodies; reagents for scientificlaboratoryanalysisresearchmedical researchtestinginspectiondetecting or verification useother than for medical purposes; reagents for scientific or medical research use for use in the development of antibodiesother than for medical or veterinary purposes; reagents for scientific or medical research use for use in scientific apparatus for chemical or biological analysis; stem cells and reconstituted cells for research or scientific purposes; reconstituted cells for the efficiency and tolerance testing of pharmaceutical products for research or scientific purposes; antibodies and antibodies-based chemicalsfor use in industry and scienceexcept for medical or veterinary use; biological preparation for use in cell cultures other than for medical or veterinary use; all of the foregoing for use in the manufacture of pharmaceuticals
Class 5
Medical and veterinary preparations for the treatment of neurodegenerative disorders; medical and veterinary articlesdiagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents for use in disease testing; pharmaceutical preparations and substances for the treatment of neurodegenerative disorders; biochemical preparations for medical use for the treatment of neurodegenerative disorders; pharmaceutical preparations and medical preparations for the treatmentprevention and diagnosis of Alzheimer's diseaseParkinson's disease and other neurodegenerative diseases and disorders of the central nervous system; antibodies and antibodies-based pharmaceutical preparations for medical purposes; diagnostic preparations for medical or veterinary purposes; medical therapeutic agents for neurodegenerative disorders; reagents for medical use; diagnostic biochemical biomarker reagents for medical use; diagnostic biomarker reagents for medical purposes; live organs and tissues for surgical implantation purpose; cells for medical use; stem cells for medical purposes; sanitary preparations for medical purposes; dietetic substancesdietetic foods adapted for medical purposes; diagnostic materialsdiagnostic kits consisting primarily of probesbuffersreagents for use in testing for neurological disorders and central nervous system disorders
Class 10
Medical and veterinary apparatus and instrumentssyringes for medical purposessyringes for injectionshypodermic syringes; medical imaging apparatus; medical apparatus and devices for the diagnosis and treatment of neurological disorders and central nervous system disorders
Class 42
Scientific and technological servicesscientific research and product development and designin the field of neurodegenerative disorders; medical and pharmacological research services; medicalpharmaceutical and biotechnological laboratory research services; scientific investigations for medical purposes; medical and scientific servicesnamely medical and scientific research services in the field of the central nervous systembrain disorders and central nervous system related disordersdiseases and pharmaceuticals; medical and scientific research in the field of neurological and neurodegenerative diseases; conducting clinical trials for others; providing scientific information about the results of clinical trials for pharmaceutical products; biochemical analysis and research; drug discovery services; pharmaceutical products development and evaluation
Class 44
Human healthcare services; medical services; providing medical information; physical examination services; rental of medical machines and apparatus; providing information relating to the rental of medical machines and apparatus; medical diagnostic testing services; optical imaging for medical diagnostic use being medical imaging services; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical testing for diagnostic or treatment purposes
Class 45
Legal services; licensing of research and development methods; licensing of intellectual property
Publications
History of USPTO decisions and trademark events.
38 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/16/2022
FIMP
FINAL DISPOSITION PROCESSED
09/16/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/07/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/07/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
06/07/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/17/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
05/17/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
05/17/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/17/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/17/2022
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
04/29/2022
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
04/01/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/15/2022
PUBO
PUBLISHED FOR OPPOSITION
02/15/2022
GPNX
NOTIFICATION PROCESSED BY IB
02/14/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/26/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/26/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/26/2022
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/11/2022
ALIE
ASSIGNED TO LIE
01/11/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/10/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
01/10/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/10/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
01/10/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/10/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/14/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/13/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/13/2021
RFNT
REFUSAL PROCESSED BY IB
07/05/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/11/2021
RFRR
REFUSAL PROCESSED BY MPU
06/11/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/08/2021
CNRT
NON-FINAL ACTION WRITTEN
06/07/2021
DOCK
ASSIGNED TO EXAMINER
06/07/2021
MAFR
APPLICATION FILING RECEIPT MAILED
04/27/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/23/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/22/2021
Continuous trademark protection
Get notified about every new filing that threatens BIOARCTIC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.